{"denoms":[{"counts":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"23"},{"groupId":"BG003","value":"77"}],"units":"Participants"}],"groups":[{"description":"Patients receive cabozantinib s-malate PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15, then on day 1 beginning cycle 5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI, and blood sample collection throughout the study and undergo biopsy at screening and optionally at follow up.\n\nBiopsy Procedure: Undergo tumor biopsy\n\nBiospecimen Collection: Undergo blood sample collection\n\nCabozantinib S-malate: Given PO\n\nComputed Tomography: Undergo CT scan\n\nMagnetic Resonance Imaging: Undergo MRI\n\nNivolumab: Given IV","id":"BG000","title":"Arm A (Cabozantinib S-malate, Nivolumab)"},{"description":"Patients receive nivolumab as in Arm A. Patients may cross-over to Arm A at the time of disease progression. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI, and blood sample collection throughout the study and undergo biopsy at screening and optionally at follow up.\n\nBiopsy Procedure: Undergo tumor biopsy\n\nBiospecimen Collection: Undergo blood sample collection\n\nComputed Tomography: Undergo CT scan\n\nMagnetic Resonance Imaging: Undergo MRI\n\nNivolumab: Given IV","id":"BG001","title":"Arm B (Nivolumab)"},{"description":"Patients with diagnosis of endometrial carcinosarcoma will be enrolled in the exploratory cohort (arm C) receiving combination of cabozantinib and nivolumab and will not be part of the statistical analysis.","id":"BG002","title":"Arm C (Exploratory Cohort)"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"44","upperLimit":"77","value":"67"},{"groupId":"BG001","lowerLimit":"41","upperLimit":"83","value":"66"},{"groupId":"BG002","lowerLimit":"53","upperLimit":"83","value":"62"},{"groupId":"BG003","lowerLimit":"41","upperLimit":"83","value":"66.5"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"23"},{"groupId":"BG003","value":"77"}],"units":"Participants"}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Customized","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"23"},{"groupId":"BG003","value":"77"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"23"},{"groupId":"BG003","value":"77"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG003","value":"0"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Race and Ethnicity were not collected from any participant.","title":"Race and Ethnicity Not Collected","unitOfMeasure":"Participants"}]}